Skandinaviska Enskilda Banken (SEB)’s Nektar Therapeutics NKTR Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,972	Closed	-$414K	–	1041
2021 Q4	$414K	Sell	1,972 -2,079	-51%	-$451K	﹤0.01%	859
2021 Q3	$1.09M	Hold	4,051	–	–	0.01%	771
2021 Q2	$1.04M	Buy	+4,051	New	+$1.12M	0.01%	805
2019 Q4	–	Sell	-1,150	Closed	-$314K	–	950
2019 Q3	$314K	Sell	1,150 -973	-46%	-$357K	﹤0.01%	826
2019 Q2	$1.13M	Buy	2,123 +237	+13%	+$119K	0.01%	633
2019 Q1	$952K	Sell	1,886 -270	-13%	-$160K	0.01%	601
2018 Q4	$1.06M	Buy	2,156 +701	+48%	+$423K	0.01%	632
2018 Q3	$1.33M	Sell	1,455 -146	-9%	-$125K	0.01%	611
2018 Q2	$1.17M	Buy	1,601 +634	+66%	+$731K	0.01%	594
2018 Q1	$1.54M	Buy	+967	New	+$1.25M	0.01%	470

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s NKTR Position: Q1 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 1,972 shares — an estimated $414K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in NKTR in Q1 2018 and held it in 10 quarters. The position peaked at $1.54M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

Skandinaviska Enskilda Banken (SEB) reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 1,972 Nektar Therapeutics shares in Q1 2022, an estimated $414K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Nektar Therapeutics in Q1 2018 and held it in 10 quarters.
Skandinaviska Enskilda Banken (SEB)'s Nektar Therapeutics position peaked at $1.54M in Q1 2018.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2022, filed 11 May 2022.